NEW

CMC Expertise Accelerating Biologics Development for 20 Years and Counting

Working with my co-founders, colleagues, and clients on many fascinating projects over the last twenty years has been an honor. From the founding of the firm with former Pfizer colleagues until today, we have specialized in supporting the CMC and regulatory programs...

Vaccine Development & Commercialization

As the result of the COVID-19 pandemic, the industry learned a great deal about ways in which vaccine development and market introduction can be streamlined, particularly in an emergency situation.

However, many of these learnings can be applied to advance the efficiency of effectiveness of vaccine development in general. BioTechLogic’s team of experts has deep expertise and experience working on the front lines of vaccine development.

Complete Vaccine Development Support Services

BioTechLogic has extensive experience with vaccine development and commercialization, from preclinical to market. As you are considering the fastest path to market, we are here to help.

Vaccine Development & Production

BioTechLogic has extensive experience supporting the development and commercialization of vaccines.

 

How BioTechLogic Can Help

    • Product characterization
    • Analytical method development
    • Critical Quality Attributes understanding
    • Potency assays
    • Production strategy selection and decision making
    • Comparability studies
    • Stability studies
    • Transportation strategies
    • Raw material/excipient, and other materials compliance
    • Regulatory filing support

Vaccine CMC Services

CMC Strategy

Quality Assurance

Analytical Services

Regulatory Consulting & Submissions Support

Process Development & Validation

Contract Services & Tech Transfer Support

Supply Chain Management

Inspection Readiness

Project Management

Years of Experience

Consultants

Clients

projects

Vaccine Resources

Top 10 U.S. Biopharma Clusters

Top 10 U.S. Biopharma Clusters

Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the 10 or so regions of the nation where the industry began to arise a...